AlphAIAlphAI — Financial news for AI agents
investing.com$MIRM

H.C. Wainwright reiterates Mirum stock rating on positive trial data

H.C. Wainwright reiterated a Buy rating and $202 price target for Mirum Pharmaceuticals (MIRM) after positive Phase 3 trial results for brelovitug. The stock is up 32% over the past year, trading at $94.42. Mirum reported Q3 2026 sales of $185.7M, beating estimates, but posted a wider-than-expected loss. Analysts cite strong commercial performance and pipeline potential.

Original reporting
investing.com
Published Nov 11, 2026, 12:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 12:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$MIRM
Bullish
high confidence
Mentioned
$MIRM
Relevance
9/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$MIRMBullishHigh
01

Why it matters

The AZURE-4 Phase 3 trial met its primary endpoint, prompting analysts to raise price targets and reaffirm a Buy rating.

02

Market read

Positive trial data is a catalyst for Mirum's stock, likely driving short‑term upside.

03

What to watch

Potential safety concerns in longer‑term studies and competition from other hepatitis therapies.

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

Mirum Pharmaceuticals (NASDAQ:MIRM) focuses on treatments for chronic hepatitis delta virus.

Company-level read

Ticker impact

$MIRMBullishHigh confidence
Context

Mirum reported positive Phase 3 AZURE-4 trial results and analysts raised price target to $202.

Expected impact

likely upside as investors price in the efficacy data and higher price target.

Evidence & confidence

Phase 3 success is material for a biotech and drives near‑term buying pressure.

Market effects

Sector

Strengthens the hepatitis delta therapy space and may lift peer biotech valuations.

Regional

U.S. biotech sector could see modest gains on the news.

Global

Limited to biotech investors; no broad market effect.

Counterpoint

What could challenge this read

If the data does not translate into regulatory approval, the stock could be overbought.

Key entities

  • analyst
    H.C. Wainwright

    Reiterated Buy rating and raised price target to $202.

  • analyst
    Raymond James

    Raised price target to $189.

  • analyst
    Citizens

    Raised price target to $167.

Read at source← All news

Related articles

$MIRMHighAI 9/10

Mirum Pharmaceuticals' Brelovitug Meets Primary Endpoint In Phase 3 AZURE-4 Study

Mirum Pharmaceuticals (MIRM) reported that its Phase 3 AZURE-4 study of brelovitug for chronic hepatitis delta virus met its primary endpoint. 59% of patients on the 300 mg weekly dose and 44% on the 900 mg monthly dose achieved virologic response and ALT normalization, versus 0% in the delayed-treatment group. The drug was well-tolerated. MIRM shares traded at $93.18 after hours.

rttnews.com
$MIRMHighAI 9/10

Mirum Pharmaceuticals: AZURE-4 Meets Primary Endpoint for Brelovitug

Mirum Pharmaceuticals reported that brelovitug met the primary endpoint in its Phase 3 AZURE-4 study for chronic hepatitis delta. At week 24, 59% of patients on 300 mg weekly and 44% on 900 mg every four weeks achieved the primary endpoint, compared to 0% with delayed treatment. The company plans to submit a BLA in the first half of 2027 and expects a potential U.S. launch in Q4 2027 if approved.

tradingview.com
$MIRMHighAI 9/10

Mirum Pharmaceuticals, Inc. (MIRM): Announcement that Primary Endpoint Met in AZURE-4 Phase 3 Study and Highlights Long-Term Brelovitug Data Presented at American Association for the Study of…

Mirum Pharmaceuticals, Inc. (MIRM) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. Announcement that Primary Endpoint Met in AZURE-4 Phase 3 Study and Highlights Long-Term Brelovitug Data Presented at American Association for the Study of Liver Diseases (“AASLD”) On November 10, 2026, Mirum Pharmaceuticals, Inc. (the “Company”) announced

SEC EDGAR 8-K
$MIRMMedAI 9/10

Mirum’s brelovitug meets primary endpoint in second phase 3 trial

Mirum Pharmaceuticals (MIRM) reported that brelovitug met the primary endpoint in the Phase 3 AZURE-4 trial for chronic hepatitis delta virus, with 59% and 44% of patients achieving the combined endpoint in the two treatment arms. The drug has FDA Breakthrough Therapy and Orphan Drug Designations. Mirum plans to submit a Biologics License Application to the FDA in the first half of 2027.

investing.com